Nycomed gets veltuzumab rights from Immunomedics; deal terminated
Immunomedics (antibodies) has granted Nycomed exclusive worldwide rights to develop, manufacture, and sell its veltuzumab for all non-cancer indications.
- Specialty Pharmaceuticals
- Large Molecule
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.